TRIUMPH-2 · 2026-09-29
Retatrutide: new weight-loss results, but not available yet
The results are encouraging, but this medicine is still being developed. There is no need to switch treatment now.
This is news about a medicine in development—not a treatment currently available at the clinic.
What did the study find?
The trial followed 1,152 adults with type 2 diabetes and overweight or obesity for 80 weeks. Here is one dose compared with placebo.
| Study group | Weight lost |
|---|---|
| Retatrutide 12 mg | 20.8% |
| Placebo (no active medicine) | 4.0% |
These estimates assume continued study treatment without prohibited treatments. They are not a promise for an individual, and separate trials cannot establish which medicine works best.
Side effects still matter
Nausea, diarrhea, constipation and vomiting occurred. Greater weight loss does not mean a medicine suits everyone.
What does this mean for you now?
As of 2026-09-30, retatrutide is still investigational, cannot be prescribed by this clinic, and has no confirmed Taiwan launch date. Continue your agreed care plan. Do not buy online products labeled for research use.
Source
Based on Lilly’s TRIUMPH-2 phase 3 announcement dated 2026-09-29, not a full review of the journal paper.
Lilly · TRIUMPH-2 · 2026-09-29